Primena imunohistohemijskih markera P16, P63, ciklin D1 i morfometrijske analize u proceni težine displazije grlića materice
Sažetak
Uvod/Cilj. Infekcija humanim papiloma virusima (HPV) je glavni etiološki faktor za razvoj displastičnih, skvamoznih intraepitelnih lezija (SIL) grlića materice. Virusni onkoproteini utiču na gene i proteine koji su uključeni u deobu ćelije. Cilj istraživanja je bio da se ispita efekat primene imunohistohemijskih markera koji se odnose na proteine uključene u ćelijski ciklus, kao i primene morfometrijskijske analize jedara u proceni težine displazije grlića materice. Metode. U retrospektivno istraživanje je bilo uključeno 78 žena kod kojih je potvrđeno prisustvo visoko rizičnih tipova humanih papiloma virusa (HPV) metodom polymerase chain reaction (PCR), a histološki je dijagnostikovana SIL niskog (LSIL) ili visokog (HSIL) stepena. Izvršene su imunohistohemijske analize p16, p63 i cyclin D1 i morfometrijska analiza površine jedara. Kontrolnu grupu činilo je 10 žena kod kojih nije potvrđeno prisustvo HPV virusa, niti SIL lezije. Studija je sprovedena uz poštovanje principa Helsinške deklaracije. Rezultati. Ustanovljena je statistički visoko značajna razlika u imunohistohemijskoj ekspresiji markera p16 i p63 (p < 0,001) između kontrolne grupe i LSIL i HSIL grupa i statistički značajna razlika u ekspresiji cyclin D1 (p < 0,05) između ovih grupa. Morfometrijska analiza površina jedara pokazala je visoko statistički značajnu razliku (p < 0,001) između ispitivanih grupa. Zakljucak. Studija je pokazala da imunohistohemijske analize p16, p63 i cyclin D1 imaju značaja u dijagnostici SIL grlića materice. Takođe, pokazano je da je morfometrijska analiza jedara cervikalnih ćelija veoma značajna u dijagnostici
displazije.
Reference
Mihajlović J, Pechlivanoglou P, Miladinov-Mikov M, Zivković S, Postma MJ. Cancer incidence and mortality in Serbia 1999-2009. BMC Cancer 2013; 13: 18.
Naumovic T, Miljus D, Djoric M, Zivkovic S, Perisic Z. Mortality from cervical cancer in Serbia in the period 1991-2011. JBUON 2015; 20(1): 231‒4.
Izadi-Mood N, Asadi K, Shojaei H, Sarmadi S, Ahmadi SA, Sani S, et al. Potential diagnostic value of P16 expression in premalignant and malignant cervical lesions. J Res Med Sci 2012; 17(5): 428‒33.
Balasubramaniam S, Balakrishnan V, Ein Oon C, Kaur G. Key Molecular Events in Cervical Cancer Development. Medicina 2019; 55: 384.
Cooper DB, McCathran CE. Cervical Dysplasia. StatPearls (In-ternet). Treasure, Island (FL): StatPearls Publishing; 2019. Available from: https://www.ncbi.nlm.nih.gov/
books/NBK430859/
Sahasrabuddhe VV, Luhn P, Wentzensen N. Human papilloma-virus and cervical cancer: biomarkers for improved prevention efforts. Future Microbiol 2011; 6(9): 1083‒98.
Zhu Y, Ren C, Yang L, Zhang X, Liu L, Wang Z. Performance of p16/Ki67 immunostaining, HPV E6/E7 mRNA testing, and HPV DNA assay to detect high-grade cervical dysplasia in women with ASCUS. BMC Cancer 2019; 19(1): 271.
Houghton O, McCluggage WG. The expression and diagnostic utility of p63 in the female genital tract. Adv Anat Pathol. 2009; 16(5): 316‒21.
Chen Y, Peng Y, Fan S, Li Y, Xiao ZX, Li C. A double dealing tale of p63: an oncogene or a tumor suppressor. Cell Mol Life Sci 2018; 75(6): 965‒73.
Little L, Stewart CJ. Cyclin D1 immunoreactivity in normal endocervix and diagnostic value in reactive and neoplastic en-docervical lesions. Mod Pathol 2010; 23(4): 611‒8.
Zheng W, Fadare O, Quick CM, Shen D, Guo D. Gynecologic and obstetric pathology. Singapore: Springer; 2019.
Portari EA, Russomano FB, de Camargo MJ, Machado Gayer CR, da Rocha Guillobel HC, Santos-Rebouças CB, et al. Immunohisto-chemical expression of cyclin D1, p16Ink4a, p21WAF1, and Ki-67 correlates with the severity of cervical neoplasia. Int J Gynecol Pathol 2013; 32(5): 501‒8.
Keating JT, Cviko A, Riethdorf S, Riethdorf L, Quade BJ, Sun D, et al. Ki-67, cyclin E, and p16INK4 are complimentary surro-gate biomarkers for human papilloma virus-related cervical neoplasia. Am J Surg Pathol 2001; 25(7): 884‒91.
Krishnappa P, Mohamad IB, Lin YJ, Barua A. Expression of P16 in high-risk human papillomavirus related lesions of the uter-ine cervix in a government hospital, Malaysia. Diagn Pathol 2014; 9: 202.
Witkiewicz AK, Knudsen KE, Dicker AP, Knudsen ES. The mean-ing of p16(ink4a) expression in tumors: functional signifi-cance, clinical associations and future developments. Cell Cy-cle 2011; 10(15): 2497‒503.
Nam EJ, Kim JW, Hong JW, Jang HS, Lee SY, Jang SY, et al. Expression of the p16 and Ki-67 in relation to the grade of cervical intraepithelial neoplasia and high-risk human papillo-mavirus infection. J Gynecol Oncol 2008; 19(3): 162‒8.
Li Y, Liu J, Gong L, Sun X, Long W. Combining HPV DNA load with p16/Ki-67 staining to detect cervical precancerous lesions and predict the progression of CIN1-2 lesions. Virol J 2019; 16(1): 117.
Schiffman M, Castle PE, Jeronimo J, Rodriguez AC, Wacholder S. Human papillomavirus and cervical cancer. Lancet 2007; 370(9590): 890‒907.
Conesa-Zamora P, Doménech-Peris A, Orantes-Casado FJ, Ortiz-Reina S, Sahuquillo-Frías L, Acosta-Ortega J, et al. Effect of hu-man papillomavirus on cell cycle-related proteins p16, Ki-67, Cyclin D1, p53, and ProEx C in precursor lesions of cervical carcinoma: a tissue microarray study. Am J Clin Pathol 2009; 132(3): 378‒90.